Site updated at Wednesday, 22 June 2016

Living with Dementia


Eli Lilly Announces FDA Approval of Amyvid For Alzheimer’s Assessment

Eli Lilly and Company (NYSE: LLY) and Avid Radiopharmaceuticals, Inc., a wholly owned subsidiary of Lilly, today announced the U.S. Food and Drug Administration (FDA) approval of Amyvid™, a radioactive diagnostic agent indicated for brain imaging of beta-amyloid plaques in patients with cognitive impairment who are being evaluated for Alzheimer’s Disease and other causes… Eli Lilly Announces FDA Approval of Amyvid For Alzheimer’s Assessment   

FDA OKs Agent to Differentiate Alzheimer’s

The FDA has approved the radioactive diagnostic agent florbetapir (Amyvid) for evaluation of the causes of cognitive decline, including Alzheimer’s disease, according to Eli Lilly, developer of the compound.

Florbetapir is used in conjunction with positron emission tomography to evaluate the burden of amyloid plaques in the brain, according to Daniel Skovronsky, MD, PhD,… FDA OKs Agent to Differentiate Alzheimer’s   

What is dementia?

antihypertensive drugs1 - visuospatial deficits1 - acute excitement1 - magnetic resonance spectroscopy1 - prevention of delirium1 - spread of alzheimers1 - department of psychiatry and psychotherapy1 - alzheimer's plaques1 - alpha-synuclein proteins1 - huntington's1 - parkinsons related dementia1 - single-photon emission computed tomography1 - alzheimer's markers1 - atherosclerotic plaques2 - brain imaging1 - emotional symptoms1 - tavi2 - hiv infection1 - apoe2 - sleep tied to alzheimer's1 - cyclophilin a1 - parkinson's symptoms3 - spect1 - risperidone2 - functional activation studies1 - anti-hypertension medication1 - simplicity1 - solanezumab1 - neocortex1 - sleep disturbances1 -